Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. (14th June 2022)

Record Type:
Journal Article
Title:
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. (14th June 2022)
Main Title:
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
Authors:
Pokorna, Petra
Lakka Klement, Giannoula
Vasikova, Alzbeta
Kanderova, Veronika
Jezova, Marta
Noskova, Kristyna
Mudry, Peter
Kyr, Michal
Merta, Tomas
Bajciova, Viera
Krenova, Zdenka
Palova, Hana
Valik, Dalibor
Zdrazilova Dubska, Lenka
Slaby, Ondrej
Sterba, Jaroslav
Abstract:
Is Part Of:
JCO precision oncology. Volume 6(2022)
Journal:
JCO precision oncology
Issue:
Volume 6(2022)
Issue Display:
Volume 6, Issue 2022 (2022)
Year:
2022
Volume:
6
Issue:
2022
Issue Sort Value:
2022-0006-2022-0000
Page Start:
Page End:
Publication Date:
2022-06-14
Subjects:
Precision Medicine
Neoplasms
Pharmacogenetics
Molecular Targeted Therapy
Personalized medicine
Oncology
Pharmacogenomics
Periodical
Periodicals
616.994
Journal URLs:
http://po.jco.org ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1200/PO.21.00525 ↗
Languages:
English
ISSNs:
2473-4284
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22810.xml